Arbutus Biopharma Announces $230M Modified Dutch Auction Tender Offer

What Happened
On August 21, 2026, Arbutus Biopharma Corporation (ABUS) announced plans to launch a modified “Dutch auction” tender offer to purchase up to US$230 million in value of its common shares at a price range of US$5.00 to US$5.75 per share. The company filed an 8-K to disclose the planned offer and the related press release; the tender offer has not yet commenced.

Key Details

• Planned repurchase amount: up to US$230 million in common shares.
• Price range: US$5.00 to US$5.75 per share.
• Status: Tender offer described has not yet commenced; there is no assurance it will begin on these terms or at all.
• Next steps: On commencement, Arbutus will file a Schedule TO (offer to purchase, issuer bid circular, letter of transmittal and other materials) with the SEC and Canadian regulators; those materials will be the definitive terms.

Why It Matters
A tender offer signals the company’s intent to return capital to shareholders and can affect share supply and trading dynamics if executed. Investors should watch for the Schedule TO and the official offer materials (to be filed with the SEC and SEDAR+) before making decisions, since those documents will contain the final terms, conditions and instructions for participation.